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Abstract
The United States Environmental Protection Agency (EPA) screens thousands
of chemicals primarily to differentiate those that are active vs inactive for different
types of biological endpoints. However, it is not feasible to test all possible com-
binations of chemicals, assay endpoints, and concentrations, resulting in a majority
of missing combinations. Our goal is to derive posterior probabilities of activity for
each chemical by assay endpoint combination. Therefore, we are faced with a task
of matrix completion in the context of hypothesis testing for sparse functional data.
We propose a Bayesian hierarchical framework, which borrows information across
different chemicals and assay endpoints. Our model predicts bioactivity profiles of
whether the dose-response curve is constant or not, using low-dimensional latent at-
tributes of chemicals and of assay endpoints. This framework facilitates out-of-sample
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prediction of bioactivity potential for new chemicals not yet tested, while capturing
heteroscedastic residuals. We demonstrate the performance via extensive simulation
studies and an application to data from the EPAs ToxCast/Tox21 program. Our
approach allows more realistic and stable estimation of potential toxicity as shown
for two disease outcomes: neurodevelopmental disorders and obesity.
Keywords: Bayesian hierarchical; Bioactivity profiles; Dose-response modeling; Heteroscedas-
ticity; Latent factor models; Multiple testing; ToxCast/Tox21
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1 Introduction
The United States Environmental Protection Agency (EPA) has been charged with main-
taining a chemical inventory and regulating hazardous chemicals since the Toxic Substances
Control Act in 1976. As massive numbers of new chemicals have been added to the existing
list of untested chemicals, the EPA has struggled to keep up with screening chemicals to
measure their potential toxicity and hazards to human health. The traditional animal or
in vivo testing paradigms are infeasible due to financial and time constraints (Dix et al.,
2007; Judson et al., 2010); in addition, it is desirable to minimize animals used in any
testing procedure. Therefore, a high-throughput screening (HTS) mechanism based on in
vitro assays and a large number of chemicals has been developed, enabling the EPA to
operate the relatively low-cost and rapid Toxicity Forecaster (ToxCast) and Toxicology in
the 21st Century (Tox21). These programs are designed to identify chemicals that likely
induce toxicity in humans and prioritize them for further testing (Judson et al., 2010).
The ToxCast/Tox21 program tests thousands of chemicals against numerous high-
throughput assay endpoints. Although the HTS mechanism has provided a relatively cheap
and quick way to conduct millions of tests, it is still only possible to test a small minority of
all (chemical, assay endpoint) combinations. This leads to many non-tested combinations,
which are shown as empty cells in Figures 1 & 2. Figure 1 illustrates the ToxCast/Tox21
data structure relevant to obesity; many cells have zero observations, and the number of
observations largely fluctuates across cells. Here, an observation is the result from an exper-
iment where a chemical is applied to an assay endpoint at a certain dose. Figure 2 provides
additional details on a few cells from Figure 1, including the observed measurements. Some
cells have few observations, while others have multiple replicates at a finer grid of doses.
These data can be arranged as matrix-structured sparse functional data, with the rows of
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Figure 1: Heat map of the number of observations in ToxCast/Tox21 data for obesity, based on
30 chemicals (rows) and 271 assay endpoints (columns).
the matrix corresponding to different chemicals, the columns to different assay endpoints,
and the cells containing dose-response measurements.
Traditional matrix completion focuses on the problem of filling in the missing elements
of a large matrix based on observations on a small proportion of the cells. Typically, the
observed cells contain a scalar that is assumed to be measured without error. A classic
application is recommender systems (Koren, 2009; Rendle et al., 2009) in which rows are
users, columns are products, and the observations are user ratings of products, though
matrix completion applications are broad (Candes et al., 2015; Lu et al., 2018; Nguyen
et al., 2019). We are faced with a latent binary matrix completion problem with each
cell containing a binary indicator of whether a particular chemical is active for a specific
assay endpoint. This is a type of matrix-structured multiple hypothesis testing problem
for assessing dose response relationships.
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Figure 2: Detailed illustration of the ToxCast/Tox21 data structure. Sample data for 7 chemicals
(rows) and 5 assay endpoints (columns). Each cell contains a set of test results of a single chemical
against one assay endpoint, which is functional data on a dose-response curve.
There have been many Bayesian approaches to multiple hypothesis testing (Scott and
Berger, 2006; Thomas et al., 2009; Scott and Berger, 2010; Li and Zhang, 2010; Scheel et al.,
2013; Wilson et al., 2014). Bayesian approaches are attractive due to their automatic
adjustment for multiplicity (Scott and Berger, 2006, 2010) by treating hyperparameters
controlling model size as unknown and informed by the data. In the typical framework,
hypotheses are considered exchangeable a priori. For example, variable selection cases
have hypotheses H0j : γj = 0 and H1j : γj = 1 in which γj is an indicator of whether
the jth variable is included for j = 1, . . . , p, and pi0 = Pr(γj = 1) ∼ Beta(a, b) is a global
parameter controlling model size. A variety of more elaborate non-exchangeable priors have
been proposed for γ = (γ1, . . . , γp)
′, designed to include “prior covariates” Zj informing
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Pr(γj = 1) (Thomas et al., 2009) and known structure among covariates represented by
an undirected graph (Li and Zhang, 2010).
There has also been some consideration of matrix-structured multiple testing. Scheel
et al. (2013) impose a generalized linear model on the prior probability of no insurance
claims in municipality i on day j. In relation to dose-response curves, Wilson et al. (2014)
test for dose effects on the mean using a generalized linear mixed effects model. The mean
effect indicator γij for a (chemical i, assay endpoint j) pair follows a Bernoulli distribution
with piij = Pr(γij = 1). Then piij is further structured with an assay endpoint random effect,
chemical-level fixed effect and a probit link: piij = Φ(αj +αxi) where x is the chemical-level
covariate. However, it is nontrivial to find informative chemical-level covariates xi in this
context. In their ToxCast/Tox21 application, Wilson et al. (2014) found their covariate,
chemical solubility, was not significant in explaining γij, resulting in a simplified model
with only random effects for assay endpoints.
In order to account for mechanistic similarities among chemicals and/or assay endpoints
as well as to tackle sparsity of the data, we require a more sophisticated hierarchy that
borrows information across both rows and columns of the matrix. Tansey et al. (2019)
propose hierarchical functional matrix factorization methods to infer dose-response curves,
approximating the row and the column space using low-dimensional latent attributes. How-
ever, their model lacks a formal testing framework and assumes a matrix data structure
where all cells have the same number of replicates at the same number of unique doses.
In the ToxCast/Tox21 data, the number of unique doses differs within a column, and the
number of replicates at each dose varies within a cell. Still, we can adapt low rank approx-
imations addressing matrix completion problems (Mnih and Salakhutdinov, 2008; Koren
et al., 2009; Purushotham et al., 2012; Tansey et al., 2019) to a multiple hypothesis testing
framework. We construct piij with a latent factor model, assuming that low-dimensional
6
latent attributes account for associations relevant to the mean effect among chemicals or
among assay endpoints.
Other important characteristics of the ToxCast/Tox21 data are irregular dose-response
shapes and heteroscedasticity. Many previous studies placed monotone increasing shape
restrictions on dose-response curves (Neelon and Dunson, 2004; Ritz, 2010; Wilson et al.,
2014) and did not consider heteroscedasticity. Our approach is strongly motivated by
evidence that disruption in centrality or dispersion of intricately-controlled biological path-
ways observed in vitro can lead to in vivo toxicity and ultimately connect to detrimental
health effects (Klaren et al., 2019; Knapen et al., 2020). We define any changes in mean
and variance of dose-response curves as “activity” and simultaneously model both. These
considerations provide a more holistic perspective on active chemicals than previous re-
search.
We propose a new hierarchical Bayesian matrix completion (BMC) approach for hy-
pothesis testing, which is particularly useful to tackle sparsity of the ToxCast/Tox21 data.
A posterior summary matrix of γij naturally prioritizes chemicals, putting forward those
likely to be active for further exhaustive screening. Our BMC approach is designed to cap-
ture any non-constant shapes and heteroscedastic changes of dose-response curves, while
facilitating out-of-sample prediction of bioactivity for new chemicals not yet assayed.
The remainder of the paper is organized as follows. Section 2 further explains moti-
vating aspects to develop a model tailored for the ToxCast/Tox21 application. Section
3 summarizes the ToxCast/Tox21 data of relevance to neurodevelopmental disorders and
obesity. Then, the BMC approach is described by subparts throughout section 4. We
compare the performance of BMC with existing methods on simulated data sets and show
the application results in section 5, highlighting chemicals that pose greater risks for the
two diseases. Potential areas of future research are discussed in section 6.
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2 Motivating Aspects and Relevant Literature
Hierarchical Structures
A simple approach for matrix-structured data would be to consider each cell indepen-
dently. The EPA has developed an R package “tcpl” (Filer et al., 2017) to facilitate inde-
pendent dose-response modeling of the ToxCast data. This R package provides three de-
fault models: a constant model at zero, a three-parameter Hill model, and a five-parameter
gain-loss model for each (chemical, assay endpoint) combination separately. Unfortunately,
independently inferring dose-response relationships does not have predictive power: it can-
not predict activity for cells having no data. Further, it is likely to have low power and
high variance in estimation due to the intrinsic sparsity of the ToxCast/Tox21 data shown
in Figure 1 & 2. In the ToxCast/Tox21 data, the median number of unique doses tested
for each pair is 8 (Figure S1), and about 30% of them are without replicates. Therefore,
hierarchical methods for borrowing information are crucial.
Splines without Shape Restrictions
In estimating dose-response curves, researchers have often forced parametric or mono-
tone restrictions on shapes of the curves to increase interpretability. The EPA’s default
models currently available through the tcpl package heavily depend on parametric assump-
tions and are restricted to positive responses to reduce the parameter space, requiring an
inverse transformation to fit negative responses. Wilson et al. (2014) model dose-response
functions by piecewise log-linear splines with constrained parameters to ensure responses
are monotone and non-decreasing. In the ToxCast/Tox21 data, it appears difficult to
standardize shapes of the dose-response curves (Figure 2). In addition, we observe some
examples of decreasing trends between the assay endpoint TOX21 ERa LUC BG1 Agonist
and multiple chemicals. Figure 3 shows two such examples of toxic chemicals with de-
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Figure 3: Scatter plots of two chemicals on the TOX21 ERa LUC BG1 Agonist assay endpoint.
The solid lines and gray shaded areas represent the average dose-response curves and 95% confi-
dence intervals fitted via locally estimated scatterplot smoothing (LOESS).
creasing trends. Thus, we propose a non-restricted spline model robust to any shapes of
dose-response curves, given that both upturns and downturns in dose-response functions
are suggestive of potential toxicity.
Heteroscedastic Variances
The ToxCast/Tox21 data have innate heteroscedasticity. Such heteroscedasticity is in-
evitable because dose effects are variable by nature, with variability often amplified at
high doses. Differences in the ability of assays to absorb chemical doses further inflate
this variability. That is, a certain chemical can exhibit clearer effects on some assays and
less obvious effects on others testing the same endpoint. Wilson et al. (2014) attempted
to reduce such heteroscedasticity by log transforming the data. However, data transfor-
mations may be hard to justify theoretically (Leslie et al., 2007) and may be insufficient
practically. In genetics, multiple studies have been conducted to detect genetic loci that
affect heteroscedastic errors of quantitative traits of interest (Pare´ et al., 2010; Ro¨nneg˚ard
and Valdar, 2012; Yang et al., 2012). It is widely appreciated that analyzing differences in
variance could reveal a previously unknown genetic influence and alternative biological rel-
9
evance. Although detection of heteroscedastic variances is routinely considered in genetic
analysis (Corty and Valdar, 2018), it has not been of main interest in chemical toxicity
analysis. Without data transformations, we consider heteroscedasticity as another source
of information. We compute posterior probabilities of the variance effect for observed cells.
3 Data
This paper uses data from the ToxCast/Tox21 project (invitroDBv3.2, released on March
2019), available at https://epa.figshare.com/articles/ToxCast/Tox21 Database i
nvitroDB for Mac Users/6062620. We focus on a subset of the ToxCast/Tox21 data that
contain assay endpoints relevant to neurodevelopmental disorders and obesity, along with
chemicals tested over those assay endpoints. As a result of selection criteria for chemicals
and assay endpoints described in the Supplemental Material, 30 chemicals evaluated across
131 assay endpoints are studied for neurodevelopmental disorders. These create in total
3930 cells, from which 2024 cells (51.5%) are missing. For obesity, we use the same 30
chemicals evaluated across 271 assay endpoints. Among the total 8130 cells, 3274 cells
(40.3%) contain no data.
4 Model
We specify motivations for each part of the model including the prior specification.
4.1 Matrix Completion
Primary interest lies in differentiating active and inactive chemicals. First, we conduct
multiple hypothesis testing of whether the dose-response curve is constant or not across
10
chemicals and assay endpoints. We introduce latent binary indicators {γij}, with γij = 1
denoting that the average dose-response curve is not constant for the (chemical i, assay
endpoint j) pair. Let vector γi = (γi1, . . . , γiJ)
T represent chemical i’s mean effect profile
across the J assay endpoints for i = 1, . . . ,m. We assume that chemicals and assay
endpoints explain dose effects on the mean via low rank latent features, for which we
exploit a sparse Bayesian factor model (Bhattacharya and Dunson, 2011). Since each γij
takes {0, 1} values, we impose a generalized factor model using a probit link:
Pr(γij = 1) = piij = Φ(λ
T
i ηj). (1)
A data-augmented form rewrites (1) as
γij = 1(zij > 0) where zij ∼ N(λTi ηj, 1). (2)
In this factor model, λil represents the coefficient of the lth latent pathway for the ith
chemical to have the mean effect, and ηlj represents that for the jth assay endpoint to have
the mean effect for l = 1, . . . , q and q  min(m, J). The inequality is reasonable, assuming
that not every assay endpoint (or chemical) forms an idiosyncratic latent pathway for the
mean effect. The ToxCast/Tox21 application lets either λi be treated as factor loadings
and ηj as latent factors or vice versa, depending on researchers’ interests. Provided that
one is interested in latent covariance structure among chemicals with regards to the mean
effect, a standard factor model puts a multivariate standard normal prior on latent factors
ηj ∼ Nq(0, I). Integrating out ηj from (2) yields zj ∼ Nm(0,ΛΛT + I) where Λ has λTi as
its ith row. This factor model provides a low dimensional representation of the underlying
covariance structure of chemicals. We employ a multiplicative gamma process shrinkage
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prior on factor loadings as in Bhattacharya and Dunson (2011):
λil ∼ N(0, φ−1il τ−1l ), φil ∼ Gamma (ν/2, ν/2) , τl =
l∏
h=1
ζh, l = 1, . . . , q, (3)
ζ1 ∼ Gamma(a1, 1), ζh ∼ Gamma(a2, 1), h ≥ 2. (4)
This prior choice is supported by Judson et al. (2010) who elucidated relationships be-
tween chemicals and published pathways. The authors discovered that chemicals are ac-
tivating various human genes and pathways, but the number of activated pathways varies
widely across chemicals. The multiplicative gamma process shrinkage prior tends to shrink
columns of a loading matrix towards zero through the τl’s. At the same time, it is possible
to strongly shrink only a subset of elements in a certain column through local shrinkage
parameters φil’s, retaining sparse signals.
As alternatives to the above model, we considered adding another parameter controlling
the overall proportion of γij’s equal to one. This can be accomplished through adding an
intercept and letting Pr(γij = 1) = Φ(ξ + λ
T
i ηj) or including an unknown mean at the
latent variable level as λil ∼ N(ξ, φ−1il τ−1l ). We found that, in both these cases, adding an
unknown ξ parameter did not improve results, and indeed can lead to worse performance.
This is likely due to the fact that the extra parameter is effectively redundant, leading to
an over-parameterized model. Hence, we set ξ = 0 as in (1) in all the analyses we report
in this paper.
4.2 Dose-Response Functional Data Analysis
Splines without Shape Restrictions
Let xijk be a test dose (in log base 10 scale in micromolar (µM)) of the kth measure-
ment for a (chemical i, assay endpoint j) pair, and let yijk be the corresponding response.
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Consider the model
yijk = γijfij(xijk) + 
∗
ijk,
where the error distribution is ∗ijk ∼ N(0, σ∗2ijk) for i = 1, . . . ,m, j = 1, . . . , J , and k =
1, . . . , Kij. Non-constant dose-response curves are estimated when γij = 1. We model the
dose-response function fij using cubic B-splines, which is equivalent to estimating βij in
(fij(xij1), . . . , fij(xijKij))
T = Xijβij with the B-spline basis matrix Xij of size (Kij×p). We
normalize responses and center columns of the B-spline basis matrix by (i, j) pairs prior to
any analyses in order to exclude the intercept. The prior distributions of spline coefficients
and their hyperparameters are as follows:
βij
ind.∼ Np (0,Σj) ,
Σ−1j
iid∼ Wishp(a,R−1), a, R fixed
where Ω ∼ Wishp(m,A) is a Wishart distribution in p-dimensions with E(Ω) = mA.
We suggest the following default choices for our application. As Figure 2 suggests, dose-
response functions share more similarities within an assay endpoint than between different
assay endpoints. This suggests a formulation in which spline coefficients of different chem-
icals have a common prior covariance matrix for the same assay endpoint. For assay
endpoint-specific covariance matrices, R is determined as the empirical covariance of the
ordinary least squares estimates for chemical-assay endpoint pairs. The degrees of freedom
parameter a is chosen to be p+ 2 so that Σj is loosely centered around R.
Heteroscedastic Variances
Figure S2 illustrates that ranges of responses may vary substantially by assay end-
points. This suggests modeling errors with assay endpoint-specific variances. Moreover,
we are motivated to capture heteroscedasticity to explain another dimension of chem-
ical activity. We use a log-linear model on σ2∗ijk so that log σ
∗2
ijk = δ0j + xijkδij and
13
σ∗ijk = exp(δ0j/2) exp(xijkδij/2). Here, we separate variance into an assay endpoint-specific
variability and a part that changes with dose. Reparameterizing exp(δ0j/2) with σj gives
the final model equation
yijk = γijfij(xijk) + exp(xijkδij/2)ijk, ijk ∼ N(0, σ2j ). (5)
The assay endpoint-specific variances have an inverse-Gamma distribution a priori :
1/σ2j
iid∼ Gamma
(
ν0
2
,
ν0σ
2
0
2
)
, ν0, σ
2
0 fixed.
In our application, we suggest fixing the hyperparameters ν0 at 1 and σ
2
0 at the sample
variance of the response variable to have the prior distribution weakly centered around the
vanilla estimate from data. With respect to the heteroscedastic noise, let tij = 1(δij 6= 0)
so that t indicates activity causing variance changes of responses. Prior and hyperprior
distributions of heteroscedasticity parameters are given similarly to Leslie et al. (2007):
tij
iid∼ Bernoulli(pit)
pit ∼ Unif(0, 1)
δij|tij = 1 iid∼ N(0, vδ), P r(δij = 0|tij = 0) = 1, vδ fixed.
In our case, we found that ensuring a large enough value for vδ that appropriately covers
the data range improves estimation of δij and tij. Provided that conditional standard
deviations of responses given doses can be proxies for exp(xijkδij/2) in (5), a range of δij’s
is obtained. The variance parameter vδ of δij is then determined as the square of the range
divided by 4, which makes ±2-standard deviation intervals for δij cover its sample range.
We finally fix vδ at the maximum of the above value and the sample variance of the response
variable. Combined with σ20, this allows the prior distributions of two variance parts - the
assay endpoint-specific and the heteroscedastic variance - to place enough probability on
the observed variability from data.
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In conclusion, (5) is the final model where γij is an indicator specifying whether the
ith chemical activates the jth assay endpoint in the mean, fij is a dose-response function,
the exponential term allows for heteroscedastic noise, and error is modeled with normal
distributions having assay endpoint-specific variances.
4.3 Posterior Computation
Our posterior samples are obtained using a partially collapsed Gibbs sampler and Metropolis-
Hastings steps. Most of the parameters have conjugate posterior distributions which lead
to a straightforward Gibbs sampler. Details are provided in the Supplemental Material
with code at https://github.com/jinbora0720/BMC.
5 Results
5.1 Simulations
Simulation studies were conducted to evaluate the performance of BMC in learning the
latent correlation structure among chemicals, predicting the mean effect probabilities, and
estimating the parameters. Two broad scenarios of simulations were examined correspond-
ing to data simulated from BMC (Simulation 1) or an alternative (Simulation 2). For
predictive performance, BMC was compared to three variations in the prior structure of
γij. Instead of a latent factor model, we assume simpler structures a priori as follows:
Pr(γij = 1) = pi0 ∀i, j, and pi0 ∼ Beta(1, 1); (6)
Pr(γij = 1) = pii ∀j, and pii iid∼ Beta(1, 1) ∀i; (7)
Pr(γij = 1) = pij ∀i, and pij iid∼ Beta(1, 1) ∀j. (8)
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We call models with (6), (7), (8) BMC0, BMCi, and BMCj, respectively. BMCi assumes
that each chemical has its own intrinsic mean effect probability, while BMCj assumes that
each assay endpoint has its own mean effect probability. For estimation performance,
the proposed model is compared to the zero-inflated piecewise log-logistic model (ZIPLL)
(Wilson et al., 2014) and tcpl (Filer et al., 2017). The ZIPLL code at https://github.c
om/AnderWilson/ZIPLL utilizes a Bayesian hierarchical approach whose testing framework
for the mean effect adopts (6). Since the code does not allow missing pairs in the data, we
only use ZIPLL for estimation and not prediction. The tcpl models are currently used by
EPA and treat dose-response curves independently.
In Simulation 1 in which BMC is the true data generating process, mimicking the
ToxCast/Tox21 application, the number of chemicals m was set to 30, and the number of
assay endpoints J to 150. We generate 50 data sets, and in each set we hold out 135 pairs at
random, which are 3% of the total cells in the data matrix. The profiles of the mean effect
for chemical-assay endpoint pairs were sampled assuming a factor model, which induced
a correlation structure among chemicals (Figure 4). For pairs having dose effects on the
mean, dose-response functions were given as one of the three categories: mostly increasing
and decreasing at higher doses; monotonically increasing; and decreasing. Figure 7 presents
examples of dose-response functions of each category. Heteroscedasticity is expected at one
fifth of chemical-assay endpoint combinations. More specific settings of Simulation 1 are
described in the Supplemental Material.
Figure 4 illustrates that the latent correlations relevant to the mean effect among chem-
icals are accurately estimated. Two factors (q = 2) generated the truth, and the sampler
ran with a guess of three more factors. The multiplicative gamma process shrinkage prior
helped recover the true number of factors q = 2 by shrinking factor loadings of redundant
factors to zero (Figure 5). Figure 6 displays an example of mean effect profiles. The truth
16
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to the mean effect. The results are from Simulation 1.
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Figure 5: The estimated and true entries of loading matrix Λ from Simulation 1. The estimated
Λ is identified using a varimax rotation as in https://github.com/poworoznek/infinitefact
or/blob/master/R/jointRot.R.
is adequately captured via the estimated and predicted probabilities. Results from a 5× 5
subset of the whole heap map are shown for better visualization. The complete matrices
of estimates and the truth are quite similar.
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presents the results from a 5× 5 subset chosen at random. The value in each cell of the left panel
is the posterior mean of γij . Cells with outer lines ((3,3) and (2,5) elements) are hold-out pairs
for which γij ’s are predicted.
As illustrated in Figure 7, BMC accurately captures true curves regardless of shapes.
It also produces tighter 95% credible intervals for the average dose-response curves than
competitors. The competitors, ZIPLL and tcpl models, do not seem robust enough to
various dose-response curves. In particular, ZIPLL estimates a decreasing trend as constant,
which is evident in Figure 7C. For generally increasing curves (A, B), the ZIPLL and tcpl
models sometimes miss the true dose-response functions, which becomes more noticeable
when heteroscedasticity exists. These results suggest that in some cases, BMC can lead to
more precise inferences on values estimated through dose-response curves, such as Emax
(greatest attainable response) or AC50 (chemical dose producing half maximal response in
an assay endpoint).
Table 1 summarizes simulation results when the data generating process is BMC. Only
the results from BMCj are presented because it showed slightly improved performance over
the other two. Note that Area Under the ROC Curves (AUCs) from tcpl in Table 1 & S1
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Figure 7: Dose-response curves (solid line) with fitted mean functions by BMC (long dash line),
ZIPLL (dot-dashed line), and tcpl (dashed line) in Simulation 1. The true curve is mostly in-
creasing and decreasing at higher dose in A, monotonically increasing in B, and monotonically
decreasing in C. Darker gray areas around estimated functions represent 95% credible intervals
for the average dose-response curves computed by BMC and ZIPLL, and confidence intervals by
tcpl. Lighter gray areas illustrate 95% predictive intervals from BMC for data points.
were computed slightly differently than those from other methods. BMC, three variations,
and ZIPLL all produce probability of active responses, which can be any value between 0
and 1. In order to evaluate the accuracy of estimates compared to the true γij ∈ {0, 1}
values, ROC curves and the corresponding AUCs are computed by changing thresholds
between 0 and 1. On the other hand, EPA provides a binary hit-call variable for the mean
effect through ToxCast/Tox21 based on invitroDBv2. We hereafter refer to this variable
as EPA’s hit-call. The EPA’s hit-call identifies a pair as active if the fitted Hill or gain-
loss model have lower Akaike information criterion than a constant model, and both the
estimated and observed maximum responses exceed a cutoff chosen for the assay endpoint.
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Table 1: Summary of results from Simulation 1. Root Mean Squared Error (RMSE), Area Under
the ROC curve (AUC) results for probability of the mean effect, and AUC for probability of
the variance effect are presented. The displayed values are the mean (standard error) across 50
simulations.
BMC BMCj ZIPLL tcpl
RMSE 0.403 (0.018) 0.398 (0.017) 0.821 (0.034) 0.645 (0.017)
In-sample AUC for γij 0.997 (0.001) 0.996 (0.001) 0.669 (0.007) 0.856 (0.007)
Out-of-sample AUC for γij 0.759 (0.085) 0.503 (0.048) - -
In-sample AUC for tij 1.000 (0.000) 1.000 (0.000) - -
This classification of whether each pair is active or not is directly comparable to the true
γij without changing thresholds. In simulations, assay endpoint-specific cutoffs are set to
one standard deviation away from the median of responses for that assay.
Table 1 shows that BMC outperforms the other methods overall. In training data sets,
BMC approaches (BMC and BMCj) have lower RMSEs and higher AUCs compared to
tcpl or ZIPLL. Poor performance of ZIPLL in these simulations is partially due to the
facts that monotone increasing shape restrictions fail to fit decreasing trends and that
ZIPLL does not allow for different σ2j ’s. BMC outperforming tcpl may be due to the
borrowing of information across chemicals and assay endpoints. Moreover, the original
BMC model produced in- and out-of-sample AUCs that are uniformly better than those
from BMCj. Hence, when the factor model provides a realistic characterization of the
dependence structure across assay endpoints and chemicals, it is not suggested to use a
simplified model for multiple testing. Less structure in γij results in lower out-of-sample
AUCs for γij (BMC0 : 0.485 (0.053), BMCi : 0.491 (0.049)), where BMC0 does not utilize
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chemical- or assay endpoint-specific information in prediction.
Another benefit of BMC is the capability of modeling heteroscedasticity. The AUCs
for tij in Table 1 exhibit highly accurate estimation performance for the probability of
heteroscedastic variances. Figure 7 illustrates that BMC closely recovers the true curves
even in the existence of heteroscedasticity (A and B) and that it nicely differentiates variance
changes and mean changes - for instance, the probability of the variance effect is estimated
as 0.113, while the probability of the mean effect is 1 in C. Figure 8 shows residuals
versus fitted values for the heteroscedastic pairs in Figure 7. The ZIPLL does not consider
heteroscedasticity in the model and consequently results in heteroscedastic residuals. In
contrast, BMC is able to properly account for heteroscedasticity, and residuals do not
show any patterns against fitted values. Note that in Figure 8 residuals from ZIPLL
are obtained by subtracting the fitted values from observations, while those from BMC
are the posterior mean of “normalized” residuals whose value at sth iteration is (yijk −
γ
(s)
ij f
(s)
ij (xijk))/ exp(xijkδ
(s)
ij /2).
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Figure 8: Residuals versus fitted values using BMC and ZIPLL in Simulation 1. The (normalized)
residuals and fitted values in A and B are computed using observations and fitted lines from A
and B in Figure 7, respectively.
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Simulation 2 generates data from an alternative model, ZIPLL. Despite misalignment
in data structure assumed by BMC and by ZIPLL, BMC performs similarly to or better
than ZIPLL and outperforms tcpl with respect to RMSE and AUC. The highest in-sample
AUC for γij from BMC suggests its stable estimation performance even with relatively
small number of chemicals and assay endpoints. We provide a full discussion of Simulation
2 results in the Supplemental Material.
5.2 ToxCast/Tox21 Results
This section presents results from the ToxCast/Tox21 data analysis with a focus on neu-
rodevelopmental disorders and obesity. We ran the sampler for 40,000 iterations from which
30,000 were discarded as burn-in, and every 10th sample was saved for the next 10,000 it-
erations. This long burn-in is to be conservative; trace plots and effective sample sizes for
MCMC samples indicated good mixing and apparent convergence after 15,000 iterations.
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Figure 9: Results for select chemical-assay endpoint pairs estimated by BMC to be active, having
dose effects on the mean (left) or variance (right).
Figures 9 - 11 show estimated dose-response curves from BMC as dashed lines with
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95% credible intervals as shaded areas with darker gray. The lighter gray shaded areas
illustrate 95% predictive intervals for the data points drawn as dots. “Pr(Mean Effect)” is
the mean effect probability for a (chemical i, assay endpoint j) pair, which is computed as
the posterior mean of γij. Similarly, “Pr(Var Effect)” means the variance effect probability
whose value is the posterior mean of tij. The posterior mean of pit is 0.12, meaning that
about 12% of the observed cells have heteroscedastic variances.
Figure 9 shows that BMC is able to differentiate dose effects on the mean from those
on the variance of dose-response curves. Recall that the EPA’s hit-call is an indication
of mean changes. In the left panel, BMC and the EPA agree that mean changes exist,
which is supported by an increasing trend. In the right panel, the EPA’s hit-call claims
that the average dose-response is not constant. However, BMC estimates that the mean
curve is constant at zero with probability 0.75, but with there being clear evidence of
heteroscedasticity. Therefore, Figure 9 suggests that (1) the EPA’s hit-call for the mean
effect might be misled by heteroscedastic variances; and (2) BMC can separate mean and
variance effects (at least in some cases).
Figure 10 illustrates some cases where BMC and the EPA’s hit-call disagree, and BMC’s
result is more plausible. The EPA’s hit-calls say no activity in the mean for both plots, while
BMC estimates them to be active with high probability. In these cases, not only do plots
show increasing trends of dose-response measurements, but also background knowledge
supports BMC’s estimates. In fact, Bisphenol A (BPA) and phthalates are known to disrupt
the endocrine system, which potentially results in neurodevelopmental disorders (Tran and
Miyake, 2017) and obesity (Holtcamp, 2012). In addition, chemicals activating PPARγ
receptors are potential obesogens because PPARγ is a master regulator in formulating fat
cells (Evans et al., 2004). Therefore, it is not unexpected for BPA and Dibutyl phthalate
to be active for the assay endpoint, ATG PPARγ TRANS up. Several pieces of evidence
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Figure 10: Results for select chemical-assay endpoint pairs estimated by BMC to be active,
having dose effects on the mean.
reinforce the validity of results from BMC over the EPA’s hit-call.
Figure 11 shows cases where the EPA’s hit-call can have low power because it misses
signals manifest in the variance instead of the mean. Given that phthalates are related to
obesity, we expect disruptive patterns on assay endpoints presenting toxicity of Diisobutyl
phthatlate and Di(2-ethylhexyl) phthatlate. However, the EPA’s hit-call suggests that
these phthalates are not active at the doses tested. This may be true in terms of mean
changes, but variances seem clearly heteroscedastic.
Figures 12 and S3 show predicted results for hold-out pairs. Note that we do not
predict observations or the average dose-response curves. BMC only predicts the mean
effect probability, which is often the primary focus of many studies and helps researchers
to prioritize chemicals for further testing.
Figure 12 displays advantages of BMC’s probabilistic approach to evaluate dose effects
on the mean. The left and right panels exhibit seemingly identical dose-response results
of the same chemical and different assay endpoints. These pairs have different mean ef-
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Figure 11: Results for select chemical-assay endpoint pairs estimated by BMC to be active,
having dose effects on the variance.
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Figure 12: Results for select chemical-assay endpoint pairs with seemingly identical measurements
but predicted by BMC to have different probabilities of the mean effect.
fect probabilities that reflect different assay endpoint effects. The chemical p,p’-DDE is
predicted to cause mean changes in dose-response curves with average probability of 0.806
across assay endpoints. Across chemicals, the assay endpoint BSK SAg CD38 down (left)
is more likely to have the mean effect with the average posterior probability 0.875 than
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BSK 3C IL8 down (right) with 0.691. Hence, the predicted probabilities for the mean ef-
fect can be thought to be pulled towards the probability of each assay endpoint from the
chemical’s probability. This implies that BMC appropriately addresses chemical and assay
endpoint effects in the mean effect probabilities through the latent factor model. On the
other hand, the EPA’s hit-call is 1 for both cases. Their deterministic approach might
not always be informative when researchers attempt to arrange chemicals by evidence of
toxicity. When the researchers are more informed by the probabilities, however, they can
easily prioritize chemicals - even choosing among those with the same hit-call.
We observed seemingly active pairs with mean changes can have a wide range of mean
effect probabilities. (Refer to Figure S3 for some relatively active pairs.) In fact, we found
that in the ToxCast/Tox21 application, 95% highest density intervals for the estimated
and predicted γij’s are (0.209, 1) and (0.479, 0.848), respectively. These suggest the lack
of conclusive evidence of inactivity in most cases, while the EPA’s hit-call forces chemical-
assay endpoint pairs to be classified as active or inactive. The EPA’s hit-call may tend to
flag too many pairs as inactive.
As discussed so far, it is valuable to assess toxicity of chemicals based on their activity
probability, which could be computed as Pr(γij = 1 ∪ tij = 1) = 1− Pr(γij = 0 ∩ tij = 0).
Figure 13 shows chemicals by the order of average activity probability over obesity-related
assay endpoints. Top chemicals that are most likely to disrupt biological processes asso-
ciated with obesity include p,p’-DDE, Dichlorodiphenyltrichloroethane (DDT), Triclosan,
BPA, 2,4,5-Trichlorophenol, Chlorpyrifos, and Benzyl butyl phthalate. The rankings of
chemicals by BMC and by the EPA’s hit-call show subtle differences.
Chemicals are similarly ranked by the average probability over assay endpoints related
to neurodevelopmental disorders (Figure S4). Top chemicals that are most likely to disrupt
neurodevelopmental processes include Triclosan, DDT, 2,4,5-Trichlorophenol, p,p’-DDE,
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Figure 13: Chemical ranks by the average activity probability from BMC (dots) and the average
hit-call from EPA (triangles) over obesity-related assay endpoints.
Fenpropathrin, 2-Hydroxy-4-methoxybenzophenone, and BPA. Between the two sets of
the most active chemicals associated with neurodevelopmental disorders and obesity, five
chemicals - Triclosan, BPA, 2,4,5-Trichlorophenol, DDT, and p,p’-DDE - overlap, and we
call them the top 5 chemicals. These bioactivity rankings are based on the data that are
currently available. As data expand, it will be informative to revisit such rankings.
Figure 14 provides a list of assay endpoints of relevance to neurodevelopmental disorders,
which are highly likely (> 0.9) to be “activated” by the top 5 chemicals. The list includes
both agonist and antagonist assays, and thus the “activated” probability encompasses
agonist and antagonist directions in the mean effect. The assay endpoints in the list are
expected to have important implications in disease progression, from which thirty-one assay
endpoints show impacts on both disease classes. The same list for the obesity-related assay
endpoints is provided in the Supplemental Material (Figure S5).
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Figure 14: Ranks of assay endpoints associated with neurodevelopmental disorders in terms
of probabilities to be activated by the top 5 chemicals. Only a subset of assay endpoints have
activation probabilities higher than 0.9. The assay endpoints with dots are marked uniquely for
neurodevelopmental disorders, while those with triangles are marked for two disease classes.
To study sensitivity of rankings to the choice of chemicals, we expanded our analysis to
326 chemicals. They consist of the original 30 chemicals and those screened in Phase I of
the ToxCast that have been exclusively used in other toxicity studies including Martin et al.
(2010) and Wilson et al. (2014). Within this larger collection, relative positions of the 30
chemicals remained intact with a few exceptions. BPA and Triclosan were positioned lower
in the larger set, while Cyfluthrin and MEHP were positioned higher. One of explanations
for these shifts is an altered correlation structure among chemicals. The Phase I chemicals
are mostly pesticides, and the four chemicals might have different relationship with those
28
from what they had with the 30 chemicals in terms of the mean effect.
6 Discussion
We have proposed a Bayesian multiple testing approach for inference on activity of chemi-
cals in settings involving multiple chemicals and assay endpoints and possible heteroscedas-
ticity. Our BMC approach can be applied directly in other settings involving a similar
matrix-structured experimental design. For example, this is common in pharmaceutical
studies assessing drug activity - studies will look for evidence of activity for different health
outcomes. Also, in microbial genetics, similar designs are conducted but for different types
of bacteria and environmental conditions.
The ultimate goal of many analyses using in vitro data is to make inferences on hu-
man health and inform protective regulations. Accordingly, chemicals and assay endpoints
studied in the ToxCast/Tox21 application are carefully selected: the chemicals are also mea-
sured in human epidemiology studies, and the assay endpoints cover a variety of species
and several types of tissue targets. It will be interesting to follow up on the top ranking
chemicals for neurodevelopmental disorders and obesity outcomes identified in our analyses
to further elucidate their role in human disease risk.
When extending in vitro results to in vivo toxicity, doses need to be carefully considered.
All the results presented in the paper should be interpreted in terms of tested doses, so we
do not conclude a chemical with a high probability of inactivity is inactive at higher doses
than those tested. Simultaneously, it is recommended to ensure that the doses tested in
vitro can physiologically occur in animals/humans. This recommendation is reinforced by
Klaren et al. (2019) in which in vivo toxicity prediction using in vitro assays performs much
better with toxicokinetic modeling. Therefore, future research linking in vitro data and in
29
vivo implications could be greatly assisted by assuring dose applicability in animals/humans
as well as widening the range of tested doses.
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Figure S1: Histogram of the number of unique doses tested for each chemical-assay endpoint
pair in the ToxCast/Tox21 data related to neurodevelopmental disorders. The vertical solid line
is the median. Half the pairs have the number of tested doses less than or equal to 8.
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Figure S2: Scatter plot of the responses normalized by chemical-assay endpoint pairs. Points on
each vertical line represent responses from one assay endpoint. This figure is based on a subset
of assay endpoints.
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Figure S3: Results for select chemical-assay endpoint pairs predicted by BMC to likely have dose
effects on the mean.
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Figure S4: Chemical ranks by the average active probability from BMC (dots) and the average
hit-call from EPA (triangles) over assay endpoints related to neurodevelopmental disorders.
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Figure S5: Ranks of obesity-related assay endpoints in terms of probabilities to be activated by
the top 5 chemicals. Only a subset of assay endpoints are presented with the activated probabilities
higher than 0.9. The assay endpoints with dots are marked uniquely for obesity, while those with
triangles are marked for both diseases.
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S2 Data
This section explains our selection criteria for chemicals and assay endpoints related to neu-
rodevelopmental disorders and obesity in the ToxCast/Tox21 data. The exact procedure to
find assay endpoints of interest is as follows: First, molecules are identified that have known
associations with each disease through the Comparative Toxicogenomics Database (CTD)
(Davis et al., 2019) and Ingenuity R© PathwayAnalysis (IPA) Knowledgebase (QIAGEN Inc.,
https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/).
Here, the known associations include: molecules are biomarkers of the disease; are known
to play a role in the disease etiology; and are therapeutic targets for treatment of the dis-
ease. The databases CTD and IPA maintain curated and published associations between
molecules and diseases. It is noteworthy that they originated from a variety of species
and tissue targets. In later steps, the databases are compared to the ToxCast/Tox21 data,
whose assay endpoints were derived from different species. Moreover, the assay endpoints
in the ToxCast/Tox21 program were tested across several types of tissue targets that may
differently mediate the relationship of even the same molecular target and the same assay
endpoint. Therefore, it is important to ensure that a wide variety of species and tissue tar-
gets are well represented in both ToxCast/Tox21 and the databases from which molecular
targets are identified. Second, we filter molecular targets in ToxCast/Tox21 that over-
lap with the identified molecules from CTD and IPA. Third, we choose assay endpoints
that those overlapping molecular targets are screened over. As a result of these steps, 132
and 352 assay endpoints were identified as relevant to neurodevelopmental disorders and
obesity, respectively, which were further filtered based on chemical coverage, as detailed
below.
A partial list of chemicals is considered due to a particular interest in human data.
We featured a set of overlapping chemicals measured in ToxCast/Tox21 and an existing
observational study of environmental risk factors for neurodevelopmental disorders and
obesity. In doing so, we believe future application of the ToxCast/Tox21 results to humans
will be more viable. A total of 48 chemicals were selected, 30 of which were tested within the
above mentioned list of assay endpoints. Due to the reduced list of chemicals, the number
of assay endpoints has diminished as well. Following recommended practice (Judson et al.,
2016), we retained only the doses lower than a cytotoxicity point for each chemical, which
removed two percent of the data. We employed the cytotoxicity median values stored in
a variable “cyto pt um” in the tcpl package (Filer et al., 2017). Consequently, our final
data involve 30 chemicals and 131 and 271 assay endpoints related to neurodevelopmental
disorders and obesity, respectively.
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S3 Simulations
For all simulations, we used eight unique doses {0.301, 0.477, 0.602, 0.845, 1.000, 1.301,
1.602, 2.000} in log10 µM chosen based on the frequency of appearance in the Tox-
Cast/Tox21 data. B-spline knots are set at the minimum value, three quartiles, and the
maximum of the doses.
In Simulation 1, we generated 50 data sets with Kij = 24 at each combination of
chemical and assay endpoint, which represents 3 replicates at each of the eight doses.
Elements of η were drawn independently from the standard normal distribution. Elements
in the m× q matrix Λ were sampled as in (3) and (4) with ν = 3, a1 = 2.1, and a2 = 3.1,
following the note by (Durante, 2017). The assay endpoint-specific variances were sampled
from 1/σ2j ∼ Gamma(52 , 5×0.12 ). Heteroscedasticity is expected at one fifth of chemical-assay
endpoint combinations by setting pit = 0.2. For heteroscedastic pairs, dij was sampled from
N(2, 0.12), which gives roughly exp(xijk)ijk for the error term. For BMC and ZIPLL,
20,000 samples were drawn, of which 1,000 samples were saved and analyzed. First 10,000
samples were discarded as burn-in, and every 10th sample was retained for the next 10,000
samples. Trace plots and effective sample sizes for MCMC samples suggested convergence
and good mixing.
In Simulation 2 where misalignment exists between the true data generating process
and BMC, we generated data under the ZIPLL model. The number of chemicals m was set
to 15, and the number of assay endpoints J to 15. The bottom right 3× 3 chemical-assay
endpoint pairs were held out for prediction of γij. We generated 50 data sets with Kij = 8
so that each chemical-assay endpoint pair has one observation at each of the eight doses.
No replicates at such scarce doses make it impractical to evaluate heteroscedasticity, which
is consequently not considered in Simulation 2. The model
yijk = γijfij(xijk) + ijk, ijk ∼ N(0, 0.12)
was considered where around half the pairs were randomly assigned to have the mean effect
with γij ∼ Bernoulli(0.5). The dose-response function was
fij(xijk) = tij − tij − bij
1 + exp{wij(log xijk − log aij)}
where tij ∼ Unif(0, 10), bij = 0, aij = max(xijk), and wij ∼ Unif(1, 8). The RMSE
and AUC results are summarized in Table S1. Only the results from BMCi are presented
because it showed better predictive performance than the other two.
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Table S1: Summary of results from Simulation 2. The RMSEs and AUC results of the mean
effect probabilities are presented. The displayed values are the mean (standard error) across 50
simulated data sets.
BMC BMCi ZIPLL tcpl
RMSE 0.095 (0.002) 0.094 (0.002) 0.088 (0.002) 0.282 (0.017)
In-sample AUC for γij 0.983 (0.009) 0.981 (0.009) 0.980 (0.009) 0.907 (0.018)
Out-of-sample AUC for γij 0.556 (0.172) 0.486 (0.214) - -
It is remarkable that BMC is able to estimate dose-response trends almost as well
as ZIPLL and has higher accuracy in estimating γij even when ZIPLL is the true data
generating process. In Simulation 2, BMC and ZIPLL outperform tcpl models. Smaller
RMSEs and higher AUCs from BMC and ZIPLL compared to those from tcpl suggest
increased robustness of spline methods than parametric ones for dose-response functions.
The improved metrics also indicate benefits of hierarchical methods over the independent
curve fitting that ignores correlations between chemicals or assay endpoints. In particular,
the achievement of the highest in-sample AUC for γij from BMC is encouraging despite
the relatively small number of chemicals and assay endpoints. The disadvantage of these
small m and J , however, is apparent in poor predictive AUCs of BMC and BMCi. The
out-of-sample AUC for γij from BMC is only slightly better than random guessing (AUC
= 0.5), while the models with simpler structures on γij are not as good as random guessing
(BMC0 : 0.471 (0.208), BMCj : 0.472 (0.222)).
S4 Posterior Computation
Under the prior specification in section 4, posterior samples are obtained by iterating the
following partially collapsed MCMC sampler.
Heteroscedasticity
1. Update tij and δij simultaneously using the Metropolis-Hastings algorithm. Propose
tpij as follows: for each j, choose random number of elements and random indices to
update. For those selected (i, j) pairs, flip zero and one. Given the proposed tpij,
propose δpij using t-distribution with 4 degrees of freedom centered at the current δ
c
ij.
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Accept (tpij, δ
p
ij) with probability min{1, r} where
r =
∏Kij
k=1N(yijk − γij(xBijk)Tβij; 0, exp(xijkδpij/2)2σ2j )∏Kij
k=1N(yijk − γij(xBijk)Tβij; 0, exp(xijkδcij/2)2σ2j )
×
Bernoulli(tpij; pit){N(δpij|tpij = 1; 0, vδ)1(tpij = 1) + 1× 1(tpij = 0)}
Bernoulli(tcij; pit){N(δcij|tcij = 1; 0, vδ)1(tcij = 1) + 1× 1(tcij = 0)}
.
2. Update pit from
(pit|tij ∀i, j) ∼ Beta
(
1 + nt, 1 +
J∑
j=1
mj − nt
)
,
where nt =
∑
i
∑
j 1(tij = 1) and mj =
∑
i 1(Kij > 0).
Functional Mean
Once Steps 1&2 are completed in every iteration, the data (X, Y ) need to be refor-
mulated: yijk is replaced by yijk/ exp(xijkδij/2), and x
B
ijk by x
B
ijk/ exp(xijkδij/2).
3. Update (λi,ηj) as in (Bhattacharya and Dunson, 2011). Priors, hyperparameters
specification and posterior distributions are fully explained in (Bhattacharya and
Dunson, 2011) and (Durante, 2017). We shall not repeat the sampling algorithms for
λi and ηj here. With the sampled (λi,ηj), update piij using (1).
4. Update zij from
(zij|γij = 1,λi,ηj) ∼ TN(0,∞)(λTi ηj, 1),
(zij|γij = 0,λi,ηj) ∼ TN(−∞,0)(λTi ηj, 1)
where TN(a,b)(µ, σ
2) denotes a normal distribution truncated to the interval (a, b)
with mean µ, variance σ2.
5. Update γij from the conditional Bernoulli distribution with βij marginalized out.
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Using the following probabilities,
Pr(γij = 1|yij, Xij, σ2j ,Σj, piij)
∝ piij|ΣjXTijXij/σ2j + Ip|−1/2 × exp
(
1
2σ4j
yTijXij
(
XTijXij/σ
2
j + Σ
−1
j
)−1
XTijyij
)
,
(S1)
Pr(γij = 0|yij, Xij, σ2j ,Σj, piij) ∝ (1− piij), (S2)
(γij|yij, Xij, σ2j ,Σj, piij) ∼ Bernoulli
(
(S1)
(S1) + (S2)
)
where yij = [yij,1, . . . , yij,Kij ]
T .
6. Update βij from the conditional normal distribution only if γij = 1
(βij|γij = 1,yij, Xij, σ2j ,Σj)
∼ Np
((
Σ−1j +X
T
ijXij/σ
2
j
)−1
XTijyij/σ
2
j ,
(
Σ−1j +X
T
ijXij/σ
2
j
)−1)
.
7. Update Σj from
(
Σ−1j |β1j, . . . ,βmj ,j
) ∼ Wish
a+mj,(R + mj∑
i=1
βijβ
T
ij
)−1 .
Assay endpoint-specific variance
8. Update σ2j from
(1/σ2j |yij, γij, Xij,βij∀i = 1, . . . ,mj)
∼ Gamma
(
ν0 +
∑mj
i=1Kij
2
,
ν0σ
2
0 +
∑mj
i=1
∑Kij
k=1(yijk − γij(xBijk)Tβij)2
2
)
.
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